Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

User: Guest

Title:: Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
Document type:: Zeitschriftenaufsatz
Author(s):: Ortiz, Stephan ; Pittock, Sean J. ; Berthele, Achim ; Levy, Michael ; Nakashima, Ichiro ; Oreja-Guevara, Celia ; Allen, Kerstin ; Mashhoon, Yasmin ; Parks, Becky ; Kim, Ho Jin
Keywords:: Neurology ; autoimmune ; complement ; exposure-response analysis ; neuromyelitis optica spectrum disorder ; pharmacokinetics ; pharmacodynamics ; ravulizumab
Journal title:: Frontiers in Neurology
Year:: 2024
Journal volume:: 15
Fulltext / DOI:: doi:10.3389/fneur.2024.1332890
Publisher:: Frontiers Media S.A.
E-ISSN:: 1664-2295
Date of publication:: 31.01.2024
CC license:: by, https://creativecommons.org/licenses/by/4.0

BibTeX

Occurrences: